Tag Archive | "Gilead"

Amgen may join Gilead as biotech seeks acquisition to fuel growth

Tags: , , , ,


Written by Meg Tirrel, Ryan Flinn and Jeffrey McCracken for Bloomberg.

Amgen and Celgene may dive into deal-making this year as the biggest biotechnology companies seek to return to the industry’s high-growth roots. Read the full story

Gilead increased bid 37% as rivals demurred on Pharmasset

Tags: , , ,


Written by Ryan Flynn.

Gilead Sciences Inc. increased an offer to buy experimental hepatitis C drugmaker Pharmasset Inc several times before agreeing to pay $10.8 billion, as other potential buyers bowed out before making a bid, filings show.  Read the full story

Gilead could have had Pharmasset cheap

Tags: ,


Investors in Gilead Sciences may believe the company is paying too much to buy Pharmasset at $11 billion. Emory University researcher Raymond Schinazi, who founded Pharmasset, knows by just how much Read the full story

Who’s next in the hepatitis C acquisition trail?

Tags: , ,


The recent acquisition of Pharmasset for a record breaking drug maker acquisition by Gilead has got markets asking who will be next Read the full story

Gilead acquires Pharmasset in $11 billion mega bet on interferon-free drugs

Tags: , , ,


Gilead has acquired Pharmasset for a massive $11 billion, in one of the biggest acquisition deals of 2011 Read the full story

Gilead Sciences to acquire Pharmasset for $11 billion

Tags: , ,


Gilead Sciences and Pharmasset have announced that the companies have signed a definitive agreement under which Gilead will acquire Pharmasset for $137 per share in cash.  Read the full story

Gilead Sciences finalizes agreement with Tibotec for Prezista

Tags: , , ,


Gilead Sciences has signed a license agreement with Tibotec Pharmaceuticals for the development and commercialization of a single-tablet regimen combining Prezista (darunavir) with Gilead’s Emtriva (emtricitabine); its investigational agent GS 7340, a novel prodrug of tenofovir; and cobicistat, a pharmacoenhancer.  Read the full story

BMS and Gilead Sciences announce licensing agreement

Tags: , , ,


Licensing agreement for Bristol-Myers Squibb to develop and commercialize a fixed-dose combination containing Bristol-Myers Squibb’s protease inhibitor REYATAZ (atazanavir sulfate) and Gilead’s cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of certain HIV medicines to potentially allow for one pill once daily dosing.  Read the full story

Gilead and Boehringer sign license agreement for novel HIV inhibitors

Tags: , , , ,


Licensing agreement under which Boehringer Ingelheim has granted Gilead exclusive worldwide rights for the research, development and commercialization of its novel non-catalytic site integrase inhibitors (NCINIs) for HIV.  Read the full story

Gilead inks pact on experimental RSV treatment

Tags: , ,


Gilead Sciences and MicroDose Therapeutx have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of MDT-637.  Read the full story

cabannerad300x150new4gif
rauconbadgejpg
e80banner300x150animgif
cabannerad300x150new4gif
e80banner300x150animgif
a1banner300x150animgif